It's a monster MASH for Madrigal, as Rezdiffra quickly caught on

Forget the “bumps” analysts said about the launch of Potentia | by Madrigal Pharmaceuticals Forget the “bumps” analysts expected from Madrigal Pharmaceuticals' launch of potential blockbuster Rezdiffra. In its second full quarter on the market, the fatty liver drug brought in sales of $62 million, beating Wall Street expectations and triggering a 16% rise in Madrigal's stock price.